Azzad Asset Management Inc. ADV Buys 17,069 Shares of Becton, Dickinson and Company $BDX

Azzad Asset Management Inc. ADV raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 67.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,248 shares of the medical instruments supplier’s stock after buying an additional 17,069 shares during the period. Becton, Dickinson and Company accounts for 0.7% of Azzad Asset Management Inc. ADV’s holdings, making the stock its 21st largest holding. Azzad Asset Management Inc. ADV’s holdings in Becton, Dickinson and Company were worth $6,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the stock. Resona Asset Management Co. Ltd. boosted its stake in shares of Becton, Dickinson and Company by 2.5% during the first quarter. Resona Asset Management Co. Ltd. now owns 101,450 shares of the medical instruments supplier’s stock valued at $15,880,000 after purchasing an additional 2,511 shares in the last quarter. Seelaus Asset Management LLC increased its stake in shares of Becton, Dickinson and Company by 70.1% in the first quarter. Seelaus Asset Management LLC now owns 1,942 shares of the medical instruments supplier’s stock valued at $305,000 after buying an additional 800 shares during the period. Montag A & Associates Inc. raised its holdings in Becton, Dickinson and Company by 11.3% in the 1st quarter. Montag A & Associates Inc. now owns 6,150 shares of the medical instruments supplier’s stock valued at $967,000 after buying an additional 625 shares during the last quarter. Delta Capital Management LLC raised its holdings in Becton, Dickinson and Company by 1.2% in the 1st quarter. Delta Capital Management LLC now owns 6,945 shares of the medical instruments supplier’s stock valued at $1,092,000 after buying an additional 80 shares during the last quarter. Finally, American Capital Advisory LLC boosted its position in Becton, Dickinson and Company by 55,050.0% during the 1st quarter. American Capital Advisory LLC now owns 4,412 shares of the medical instruments supplier’s stock worth $694,000 after buying an additional 4,404 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Weiss Ratings cut shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Piper Sandler cut their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Finally, Barclays upped their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $180.29.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,188 shares of company stock valued at $765,120 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.1%

Shares of Becton, Dickinson and Company stock opened at $150.70 on Friday. The stock’s 50-day moving average is $148.11 and its 200 day moving average is $167.92. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The firm has a market cap of $41.52 billion, a price-to-earnings ratio of 38.15, a PEG ratio of 10.65 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th were paid a dividend of $1.05 per share. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.